AbbVie (Portugal)

Parent institution: AbbVie (United States)

ROR: 03em9qx04

OpenAlex ID: I4405255806

Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial

2024 · Cristina Tassorelli, Krisztián Nagy, et al. · The Lancet Neurology · 95

The design of clinical trials to support the switching and alternation of biosimilars

2016 · Freddy Faccin, Paul Tebbey, et al. · Expert Opinion on Biological Therapy · 56

Real-World Clinical, Psychosocial, and Economic Burden of Atopic Dermatitis: Results From the ESSENTIAL AD Multicountry Study

2024 · Spyridon Gkalpakiotis, Susanna Kannenberg, et al. · Dermatology and Therapy · 14

Disease severity, treatment patterns, and quality of life in patients with moderate-to-severe psoriasis routinely managed with systemic treatment: results of the CRYSTAL observational study in Central and Eastern European countries

2024 · Liisi Raam, Ilona Hartmane, et al. · Frontiers in Immunology · 13

Multidimensional Burden of Moderate-to-Severe Atopic Dermatitis in Adolescent and Adult Patients from Portugal and Greece: Results from the Global Cross-Sectional Study MEASURE-AD

2025 · Pedro Mendes-Bastos, Elisavet Lazaridou, et al. · Dermatology and Therapy · 2

PDF

OP0181 Treating to Target of Minimal Disease Activity and Normal Function in Polyarticular Juvenile Idiopathic Arthritis with Adalimumab: Analysis from A Phase 3 Clinical Trial

2014 · N. Ruperto, D. Lovell, et al. · Annals of the Rheumatic Diseases · 2

OP0006 Long-Term Safety and Effectiveness of Adalimumab in Children with Moderately to Severely Active Polyarticular or Polyarticular-Course Juvenile Idiopathic Arthritis

2014 · G. Horneff, N. Ruperto, et al. · Annals of the Rheumatic Diseases · 2

PBI46 Cost-Effectiveness of Treatment Sequences Initiating with Risankizumab for the Treatment of Moderate to Severe Psoriasis in Portugal

2020 · C. Carvalho, M. Batista, et al. · Value in Health · 1

FRI0502 Long-Term Safety of Adalimumab Treatment in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis and Enthesitis-Related Arthritis

2015 · N. Ruperto, D.J. Lovell, et al. · Annals of the Rheumatic Diseases · 1

Treating to target of minimal disease activity and normal function in polyarticular juvenile idiopathic arthritis with adalimumab: analysis from a phase 3 clinical trial

2014 · Nicola Ruperto, Daniel Lovell, et al. · Pediatric Rheumatology · 1

PDF

FRI0238 Changes in Ultrasonographic Vascularity upon Initiation of Adalimumab Combination Therapy in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate

2014 · G.S. Kaeley, M.J. Nishio, et al. · Annals of the Rheumatic Diseases · 1

Results of CRYSTAL retrospective observational study in Russia: severity of the disease, treatment landscapes and quality of life in patients with moderate to severe psoriasis receiving systemic therapy in routine clinical practice

2025 · Muza M. Kokhan, Natalia S. Rudneva, et al. · Vestnik dermatologii i venerologii

PDF

IBD-PODCAST Portugal: Proportion of Patients with Suboptimal Disease Control and Its Impact on Quality of Life in Inflammatory Bowel Disease

2025 · Helena Tavares de Sousa, Viviana Martins, et al. · GE Portuguese Journal of Gastroenterology

PCR52 Patient Reported Experience Measure (PREM) to Assess the Value of Hospital Pharmaceutical Care to Patients With Chronic Diseases

2024 · M. Melo, M. Garcia, et al. · Value in Health

Pcn162 a Cost Minimisation Analysis of 24-month Fixed Duration of Venetoclax Plus Rituximab Versus Ibrutinib for Relapsed and Refractory Chronic Lymphocytic Leukemia in Portugal

2019 · L. Silva Miguel, A.T. Paquete, et al. · Value in Health

Risk Mitigation and Preventing Medicines Shortages

2019 · João Roque, João Luís de Miranda, et al. · Lecture notes in logistics

Psy96 - Cost-effectiveness of Originator Adalimumab in Non-infectious Intermediate, Posterior and Pan-uveitis From a Societal Perspective in Portugal

2018 · A.R. Crespo, S.A. Farinha, et al. · Value in Health

Adalimumab in the treatment of moderate-severe hidradenitis suppurativa: a cost-effectiveness analysis

2017 · Borges, Sofia, Menezes, Nuno, et al. · DOAJ (DOAJ: Directory of Open Access Journals)

AB1023 Rheuma Space: Standard Practice Aiming Clinical Excellence in Rheumatology

2016 · C. Macieira, L. Cunha-Miranda, et al. · Annals of the Rheumatic Diseases

FRI0077 The Use of Ultrasound to Detect Residual Joint Inflammation in Patients with Rheumatoid Arthritis in Clinical Disease Remission

2015 · G.S. Kaeley, M.J. Nishio, et al. · Annals of the Rheumatic Diseases

THU0504 Clinical and Functional Outcomes in Patients with Polyarticular Juvenile Idiopathic Arthritis Following Treatment with Adalimumab

2015 · D. Kingsbury, P. Quartier, et al. · Annals of the Rheumatic Diseases

Works count: 21

Citation count: 189